American Tegumentary Leishmaniasis: Is Antimonial Treatment Outcome Related to Parasite Drug Susceptibility? by Yardley, Vanessa et al.
1168 • JID 2006:194 (15 October) • Yardley et al.
M A J O R A R T I C L E
American Tegumentary Leishmaniasis:
Is Antimonial Treatment Outcome
Related to Parasite Drug Susceptibility?
Vanessa Yardley,1 Nimer Ortun˜o,1,2 Alejandro Llanos-Cuentas,3 Franc¸ois Chappuis,4 Simonne De Doncker,5
Luis Ramirez,3,5 Simon Croft,1 Jorge Arevalo,3 Vanessa Adaui,3 Hernan Bermudez,2 Saskia Decuypere,5,6
and Jean-Claude Dujardin5
1London School of Hygiene and Tropical Medicine, Department of Infectious and Tropical Diseases, London, United Kingdom; 2Centro Universitario
de Medicina Tropical, Cochabamba, Bolivia; 3Instituto de Medicina Tropical “Alexander von Humboldt,” Laboratory of Molecular Parasitology,
Lima, Peru; 4Hopitaux Universitaires de Geneve, Department of Community Medicine, Geneva, Switzerland; 5Institute of Tropical Medicine,
Molecular Parasitology, and 6Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
Background. Antimonials are the firs drug of choice for the treatment of American tegumentary leishmaniasis
(ATL); however, their efficac is not predictable, and this may be linked to parasite drug resistance. We aimed to
characterize the in vitro antimony susceptibility of clinical isolates of Peruvian patients with ATL who were treated
with sodium stibogluconate and to correlate this in vitro phenotype with different treatment outcomes.
Methods. Thirty-seven clinical isolates were obtained from patients with known disease and treatment histories.
These isolates were typed, and the susceptibility of intracellular amastigotes to pentavalent (SbV) and trivalent
(SbIII) antimonials was determined.
Results. We observed 29 SbV-resistant isolates among 4 species of subgenus Viannia, most of which exhibited
primary resistance; isolates resistant only to SbIII; and 3 combinations of in vitro phenotypes: (1) parasites sensitive
to both drugs, (2) parasites resistant to both drugs, and (3) parasites resistant to SbV only (the majority of isolates
fell into this category). There was no correlation between in vitro susceptibility to both antimonials and the clinical
outcome of therapy.
Conclusion. Antimony insensitivity might occur in a stepwise fashion (firs to SbV and then to SbIII). Our
data question the definitio of true parasite resistance to antimonials. Further studies of treatment efficac should
apply standardized protocols and definition and should also consider host factors.
At present, leishmaniasis is reemerging and spreading
worldwide, because of environmental changes, host im-
munity, and treatment failure [1, 2]. The latter phe-
nomenon has been well described in the Indian sub-
continent, where, in Bihar, 160% of patients do not
respond to antimonials [3]. In other regions where the
parasite is endemic, antimonials remain the first-lin
drug. In Latin America, reports of the efficac of this
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class of drug have revealed contrasting figu es: 7% treat-
ment failure in American tegumentary leishmaniasis
(ATL) in Bolivia [4], 16% in Brazil [5], 23.9% in Peru
(G. Tulliano, F.C., and A.L.-C., data not shown), and
up to 39% in Colombia [6].
Treatment failure is a complex phenomenon with a
potentially multifactorial origin. This may involve (1)
host factors, such as genetics, immunological response
[7], characteristics of the patients [6], and clinical pre-
sentation [8]; (2) treatment features, such as drug qual-
ity [9], duration of therapy, and compliance; and (3)
parasite characteristics, such as intrinsic insensitivity
(species) [10] and drug resistance [11]. With respect to
the specifi contribution of parasite drug resistance,
reports have been inconsistent. A correlation between
resistance to pentavalent antimony (SbV) and treat-
ment outcome has been demonstrated in Leishmania
(Leishmania) donovani in India [11] but not in Sudan
[12]. In neotropical Leishmania species, a correlation
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between in vitro susceptibility and clinical phenotypes was ob-
served in patients infected with L. (Viannia) braziliensis or L.
(V.) panamensis [13]. However, in that study, parasite suscep-
tibility was determined using promastigotes (vector and culture
stage), which are known to be intrinsically insensitive to phar-
macological concentrations of SbV [14]. Very recently, a study
that focused on L. (V.) panamensis suggested that SbV resistance
define using intracellular amastigotes (the vertebrate stage)
could contribute to 40% of treatment failure [15]. However,
in that study, isolates from patients who responded to treatment
were not included; hence, the predictive value of intrinsic par-
asite drug resistance could not be completely assessed.
The present article is a part of a multidisciplinary, prospective
study aiming at a global understanding of antimony failure (see
http://www.leishnatdrug.org). We have characterized the in vi-
tro susceptibility to antimony of clinical isolates from Peruvian
patients with ATL who were treated with sodium stibogluconate
and who had different treatment outcomes. In total, 37 isolates
belonging to 5 different species endemic in Peru were included,
and particular attention was given to the most pathogenic spe-
cies, L. (V.) braziliensis. We tested the susceptibility of intra-
cellular amastigotes to SbV, which is considered to be a prodrug
[14], and to trivalent antimony (SbIII), the reduced, active form
of the drug (evidence for the role of SbIII in intracellular amas-
tigote killing has been reviewed elsewhere [14]). We then com-
pared these in vitro data to the treatment outcome of patients
from whom parasites were isolated. We are aware that parasite
tolerance to antimonies could originate from exposure to drug
or could constitute an intrinsic unresponsiveness. However,
because there is no clear answer to this question at this stage
(for parasites of subgenus Viannia), and to be consistent with
the recent literature on that subject, we have a priori used the
term “resistance” throughout the present article.
PATIENTS, MATERIALS, AND METHODS
Patients and clinical protocol. Patients with clinical suspected
cutaneous (CL), mucosal (ML), or mucocutaneous (MCL) leish-
maniasis were investigated at the Instituto de Medicina Tropical
“Alexander von Humboldt,” Lima, Peru. Infection with Leish-
mania species was confi med by direct examination of punch-
biopsy samples, parasite culture, or polymerase chain reaction
(PCR) [16]. Between November 2001 and December 2004, pa-
tients with confi med leishmaniasis were enrolled if theyprovided
written, informed consent. Pregnant women were excluded from
the study. Patients were treated with intravenous meglumine
antimoniate (Glucantime; Sanof Aventis) or generic sodium
stibogluconate (Viteco), depending on drug availability, at dos-
ages of 20 mg/kg/day for 20 (for CL) or 30 (for ML or MCL)
days. Patients who failed a firs course of SbV were treated with
a second course of SbV with or without topical imiquimod or
with conventional amphotericin B. Daily treatment was admin-
istered, under medical supervision, in outpatient clinics. All pa-
tients were asked to attend follow-up visits 1, 2, 3, 6, and 12
months after treatment. At each visit, the clinical appearance of
the lesion(s) was assessed by a physician for size and the presence
of signs of inflammatio or scarring. The status of the lesion(s)
was compared with digital pictures and drawings of the initial
(pretreatment) lesion(s) and graded from M0 (no change or
worsening of the lesion) to M4 (complete scarring of the le-
sion). Informed consent was obtained from patients or their
parents or guardians. Human-experimentation guidelines of the
Institute of Tropical Medicine were followed. Ethics clearance
was obtained from the ethical committees of the Cayetano He-
redia University, Lima, Peru, and Institute of TropicalMedicine,
Antwerp, Belgium.
Definitio of clinical outcomes. Initial cure (3 months
after treatment) was define as follows: for ulcers, complete
scarring of lesion(s) and disappearance of inflammato y signs;
for nodular lesions, flattenin and the absence of infiltratio
or other sign(s) of inflammation Unresponsiveness was define
as the absence or incomplete scarring of lesion(s) and/or the
persistence of inflammato y signs at 3 months after treatment
or the worsening of existing lesion(s) or the appearance of new
lesion(s) 3 months after treatment. Relapse was define as
the reappearance of an ulcer or nodule and/or local signs of
inflammatio after initial cure. Treatment failure was define
as unresponsiveness or relapse. Cure was define as initial cure
without relapse 12 months after treatment.
Parasites and in vitro culture. Parasites were isolated onto
3N blood slopes with a saline/antibiotic overlay [17], sent to
the Institute of Tropical Medicine (Antwerp, Belgium) cryo-
preserved in aliquots, and typed within 8 passages of isolation.
Frozen stocks were sent to the London School of Hygiene and
Tropical Medicine, where the parasites were passaged initially
onto 3N blood slopes with M199 with a 20% heat-inactivated
fetal calf serum (HIFCS) overlay and then onto M199 with
20% HIFCS alone. It was necessary to introduce the use of
M199 [18] to obtain a clean bulk culture of promastigotes that
would be sufficien for further evaluation. The type of medium
can affect the infectivity of the parasite [19]; however, in the
present study, all isolates were exposed to exactly the same
growth conditions, and the work was performed as close to the
time of isolation as possible.
Parasite species identification Leishmania species identi-
ficatio was performed by multilocus PCR–restriction fragment
length polymorphism analysis of the gp63, Hsp70, cpb, and/or
H2b genes [20–22]: restriction patterns were compared with
those of reference strains of L. (V.) braziliensis (MHOM/BO/
94/CUM43), L. (V.) guyanensis (MHOM/BR/75/M5378), L. (V.)
lainsoni (MHOM/BO/94/CUM78), L. (V.) peruviana (MHOM/
PE/90/HB22), and L. (L.) amazonensis (MHOM/BR/73/M2269).
In vitro drug-susceptibility testing. Promastigotes were
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Figure 1. Distribution of clinical Peruvian isolates tested for their sus-
ceptibility to pentavalent antimony (SbV) and trivalent antimony (SbIII).
Leishmania (Viannia) braziliensis, circles; L. (V.) guyanensis, triangles; L.
(V.) lainsoni, squares; L. (V.) peruviana, diamond; and L. (L.) amazonensis,
arc. The shading patterns represent the tested phenotype: sensitive to
both drugs, white; resistant to SbV and not tested with SbIII, light gray;
resistant to SbV and sensitive to SbIII, dark gray; and resistant to both
drugs, black.
maintained in M199 medium supplemented with 20% HIFCS
at 25C. All strains were tested for their in vitro sensitivity to
SbV within 8 passages of isolation. Late-stage promastigotes
were used to infect starch-induced murine peritoneal macro-
phages at a ratio of 7 promastigotes to 1 macrophage in Labtek
16-well tissue culture-well slides (VWR), in quadruplicate, and
kept at 34C in a 5% CO2/air mix. Twenty-four hours after
infection, 1 slide was fixe in methanol and stained with
Giemsa, for the determination of the initial level of infection.
If the level of infection was 180%, the infected cultures were
exposed to sodium stibogluconate (Sb[V]; GSK) over a dose
range of 80, 26.6, 8.8, and 2.9 mg/mL. Stock solutions of both
NaSbV and Triostam (SbIII) were formulated by dissolving the
white powder in sterile PBS, followed by further dilution in
complete medium. After 5 days, the percentage of infected
macrophages in each well was determined by microscopic anal-
ysis [23]. The percentage of inhibition was calculated from a
comparison of counts from treated and untreated cultures using
sigmoidal regression analysis (xlfi version 3; Microsoft), and
ED50 values were determined. The strain L. (V.) braziliensis
MHOM/BR/75/M2903, a World Health Organization reference
strain that is sensitive to sodium stibogluconate andmeglumine
antimoniate, was included in each assay as a reference. The
ratio of the ED50 of a tested strain to the ED50 of the reference
strain (range, 4–15 mg/mL, according to the experimental se-
ries), which we termed the “activity index” (AI), was used to
express the in vitro susceptibility of that tested strain and to
easily compare the results obtained from different series of
experiments. Sensitivity to SbIII was evaluated using the same
assay. Triostam (trivalent sodium antimonyl gluconate; donated
by Burroughs Wellcome) was used over a dose range of 30–
1.1 mg of SbIII/mL. Comparable concentrations to SbV could
not be used because of toxicity in host cells at higher concen-
trations. Animal experiments complied with UK government
(Home Office guidelines.
Data analysis. Demographic, clinical, laboratory, treatment,
and outcome data were entered into an Excel database (Excel
2003; Microsoft). All data were cross-checked with individual
patient file during several data-monitoring visits by F.C. Sta-
tistical analysis was done using SPSS (version 11.0. for Win-
dows; SPSS). For the analysis of correlations between clinical
outcome and parasite sensitivity, only patients treated with an-
timonials who had a clear clinical outcome (cure or treatment
failure) were included. Categorical variables were compared
using cross-tabulations and x2 tests, and numerical variables
(parasite sensitivity) were compared using the nonparametric
Mann-Whitney U test, at a critical a-level of .05.
RESULTS
In vitro susceptibility to SbV and SbIII. A total of 37 isolates
was selected for in vitro susceptibility assays, all but 1 of which
originated from the Amazonian forest (lowlands and high jun-
gle), because our aim was to focus on L. (V.) braziliensis isolates.
Species identificatio revealed the following composition of our
sample: L. (V.) braziliensis (26 isolates), L. (V.) guyanensis (5
isolates), L. (V.) lainsoni (4 isolates), L. (V.) peruviana (1; the
only isolate from the Andean region), and L. (L.) amazonensis
(1 isolate). The L. (V.) braziliensis isolates had a widespread
origin, whereas L. (V.) guyanensis and L. (V.) lainsoni were
essentially isolated from the central high jungle (figu e 1). All
of these isolates were tested for their susceptibility to SbV.
Strains with an AI of 1–2 (i.e., similar to that of the reference
strain) were considered to be sensitive. Strains with an AI of
5–6 (corresponding to an ED50 of 180 mg of SbV/mL) were
considered to be resistant. With 1 exception (strain PER008,
with an AI of 3), all strains that we tested belonged to 1 of
these 2 categories. Sensitive and resistant parasites were ob-
served in L. (V.) braziliensis, L. (V.) guyanensis, and L. (V.)
lainsoni, whereas the L. (V.) peruviana isolate and the L. (L.)
amazonensis isolate were resistant and sensitive, respectively
(table 1). Interestingly, the majority (22/26) of L. (V.) brazil-
iensis isolates were resistant to SbV. This was not likely due to
bias in this sample, because (1) the isolates came from different
regions of the Amazonian jungle and (2) there was a similar
proportion of cures (13) and treatment failures (11) among the
patients from whom they were obtained (the 2 remaining pa-
tients were lost to follow-up).
Table 1. Peruvian Leishmania isolates tested for their in vitro susceptibility to antimonials and link with
clinical phenotype.




MHOM/PE/01/PER 005/0 Loreto, Ucayali CL 1 ND Unresponsive
MHOM/PE/03/PER 130/0a Cusco, Echarate CL 1 0 Unresponsive
MHOM/PE/03/PER 163/0 Huanuco, Leoncio Prado CL 2 0 Definite cure
MHOM/PE/03/PER 186/0a Junin, Satipo CL 2 1 Definite cure
MHOM/PE/02/PER 086/0b Pasco, Oxapampa CL 6+ 0 Unresponsive
MHOM/PE/02/PER 011/0c Huanuco, Huanuco MCL 6+ 1 Treatment with
amphotericin B
MHOM/PE/03/PER 201/0 Loreto, Requena ML 6 1 Definite cure
MHOM/PE/03/PER 164/0 Ucayali, Coronel Portillo CL 6+ 1 Initial cure
MHOM/PE/03/PER 231/0 Junin, Satipo ML 5 2 Definite cure
MHOM/PE/01/PER 002/0 Madre de Dios, Tambopata CL 6 2 Unresponsive
MHOM/PE/03/PER 215/0 Ucayali, Coronel Portillo ML 6 2 Definite cure
MHOM/PE/02/PER 094/0 Huanuco, Puerto Inca CL 6 2 Definite cure
MHOM/PE/03/PER 260/0 Madre de Dios,
Tahuamanu
ML 6 2 Definite cure
MHOM/PE/03/PER 157/0 Madre de Dios, Tambopata CL 6+ 2 Definite cure
MHOM/PE/02/PER 015/0 Ucayali, Coronel Portillo CL 6+ 2 Unresponsive
MHOM/PE/03/PER 136/0c Ucayali, Coronel Portillo ML 6 5 Treatment with
amphotericin B
MHOM/PE/03/PER 182/0 Ayacucho, La Mar CL 6 5 Definite cure
MHOM/PE/02/PER 104/0a Madre de Dios, Tambopata CL 6+ 6+ Unresponsive
MHOM/PE/02/PER 010/0 Cajamarca, Jaen CL 6 ND Initial cure
MHOM/PE/02/PER 069/0a,c Madre de Dios, Manu ML 6 ND No treatment
MHOM/PE/01/PER 006/1 Junin, Satipo CL 6+ ND Unresponsive
MHOM/PE/01/PER 014/0a Junin, Satipo CL 6+ ND Unresponsive
MHOM/PE/01/PER 012/1 Cusco, Calca CL 6+ ND Unresponsive
MHOM/PE/02/PER 016/0 Huanuco, Puerto Inca CL 6+ ND Definite cure
MHOM/PE/02/PER 067/0a Cusco, La Convencion CL 6+ ND Unresponsive
MHOM/PE/02/PER 122/0 Madre de Dios, Tambopata CL 6+ ND Definite cure
L. peruviana MHOM/PE/01/PER 001/1 Ayacucho, Lucanas CL 6+ ND Unresponsive
L. guyanensis
MHOM/PE/01/PER 003/0 Junin, Satipo CL 1 ND Definite cure
MHOM/PE/02/PER 008/0 Pasco, Oxapampa CL 3 ND Definite cure
MHOM/PE/03/PER 132/0 Junin, Satipo CL 6+ 1 Definite cure
MHOM/PE/02/PER 054/0c Junin, Satipo CL 6+ ND Unknown
MHOM/PE/02/PER 072/0 Junin, Chanchamayo CL 6+ ND Definite cure
L. lainsoni
MHOM/PE/03/PER 127/0 San Martin, Tocache CL 1 ND Definite cure
MHOM/PE/03/PER 131/0 Junin, Chanchamayo CL 6+ 1 Definite cure
MHOM/PE/02/PER 092/0 Junin, Chanchamayo CL 6 6 Definite cure
MHOM/PE/02/PER 105/0 Madre de Dios, Tambopata CL 6+ 6+ Definite cure
L. mexicana MHOM/PE/02/PER 068/0a Ayacucho, Huanta CL 0 ND Unknown
NOTE. CL, cutaneous leishmaniasis; MCL, mucocutaneous leishmaniasis; ML, mucosal leishmaniasis; ND, not done; SbIII, trivalent
antimony; SbV, pentavalent antimony.
a Patients with a history of previous treatment with antimony.
b Patients with a history of previous treatment, but the drug used was not known.
c Patients not integrated in comparison with in vitro susceptibility data.
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Table 2. Relationship between in vitro susceptibility of clinical isolates
to antimonials and treatment outcome of respective patients.







5S 4 2 2
5R 19 8 11
5R3S 10 3 7
5R3R 2 1 1
L. (V.) guyanensis
5S 2 0 2
5R 2 0 2
L. (V.) lainsoni
5S 1 0 1
5R 3 0 3
NOTE. Only isolates for which in vitro and clinical phenotypes were available are
included. 3R, resistant to trivalent antimony (SbIII); 3S, sensitive to SbIII; 5R, resistant to
pentavalent antimony (SbV); 5S, sensitive to SbV.
Of these 37 isolates, 21 could be tested in parallel for their
in vitro sensitivity to SbIII, with only 5 isolates shown to be
resistant to the drug (AI of 5–6; table 1). The remaining 16
isolates showed AIs of 0–2 (0, more sensitive than the reference
strain M2903). When we considered the results of SbV and
SbIII together, 3 phenotypes were observed: SbV sensitive/SbIII
sensitive (5S3S), SbV resistant/SbIII sensitive (5R3S), and SbV
resistant/SbIII resistant (5R3R). A possible fourth combination,
SbV sensitive/SbIII resistant (5S3R), was not seen in this sam-
ple. The 5R3S and 5R3R phenotypes were both seen in L. (V.)
braziliensis and L. (V.) lainsoni: 5R3S parasites were more abun-
dant in the former species (11/14 isolates), whereas 2 of 3 L.
(V.) lainsoni isolates were of type 5R3R.
Geographical clustering in terms of in vitro susceptibility was
not observed. SbV-resistant isolates were seen in all regions,
and even the less frequently occurring 5R3R parasites were
found a great distance from each other. Within the same foci,
it was possible to observe different phenotypes among iso-
lates—for example, the coexistence of 5R3R and 5R3S L. (V.)
braziliensis isolates in Tambopata (eastern lowlands, close to
the Bolivian border) and of 5S3S and 5R3S parasites in Junin
(central high jungle).
In vitro susceptibility and treatment outcome. We com-
pared the results of the in vitro susceptibility of the clinical
isolates of L. (V.) braziliensis, L. (V.) guyanensis, and L. (V.)
lainsoni to the treatment outcome of the patients from whom
they were obtained (table 2). After the exclusion of 2 patients
treated with amphotericin B, 1 patient who defaulted before
the start of treatment, and 2 patients with an unclear clinical
outcome, 32 patients and isolates were included in the analysis.
There was no statistical correlation between SbV and SbIII in
vitro sensitivity of the parasite and clinical outcome when par-
asite species were analyzed together or separately. Moreover,
when the analysis was restricted to the 25 patients without prior
treatment with antimonials who had parasites isolated and
tested in vitro, we found no statistically significan association
between in vitro sensitivity and clinical outcome. Two of 4
sensitive L. (V.) braziliensis isolates came from patients with
treatment failure, and 11 of 19 resistant isolates of that species
came from cured patients. Of the 10 5R3S and 2 5R3R isolates,
7 and 1 came, respectively, from cured patients. For patients
infected with L. (V.) guyanensis and L. (V.) lainsoni, the clinical
picture was somewhat different—all of them were cured with
antimony treatment, but this was not dependent on the in vitro
susceptibility of the infecting parasites; 5 of the patients were
infected with SbV-resistant parasites.
We also analyzed the data by distinguishing L. (V.) braziliensis
isolates obtained before and after antimony treatment. “Post-
treatment” was considered broadly, as recruited patients either
(1) without a previous history of treatment with antimonials
and samples obtained after the controlled therapy of present
study or (2) with a previous history of treatment and samples
obtained before the controlled therapy of present study (labeled
with “a” and “b” table 1). Results were similar in both cate-
gories: we observed 7 SbV-resistant isolates among the 9 post-
treatment samples and 15 SbV-resistant isolates among the 17
pretreatment isolates.
DISCUSSION
Reports on antimonial resistance among clinical isolates of de-
fine neotropical Leishmania species are scanty. Early reports
described the existence of resistance to SbV in L. (V.) pana-
mensis [13], L. (V.) braziliensis [13], and L. (L.) amazonensis
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[24], but they were based on parasite promastigotes, which are
known to be intrinsically insensitive to SbV [11, 25]. This ap-
peared clearly when we compared ED50s of L. (V.) braziliensis
promastigotes (220–4100 mg/mL) [13] with those of amasti-
gotes: 4 to 180 mg/mL (present study) versus 2.6 to 1128 mg/
mL [15]. The higher ED50s reported by Rojas et al. [15] are
likely explained by differences in the respective protocols. For
the present study, macrophages were infected at a ratio of 7
parasites to 1 macrophage. Previously, it has been shown that
a higher amastigote:macrophage ratio can influenc the sodium
stibogluconate ED50 [26]. A lower dose range over a longer
exposure period (5 days) was also used in the present study,
which allowed the compound to accumulate sufficientl within
infected cells [26, 27]. This demonstrates the specificit of our
study and highlights the extreme care needed in comparing our
data with those of previous reports.
It is known that different Leishmania species may present a
different intrinsic sensitivity to antimonials. Using the amas-
tigote-macrophage model, reference strains of L. (V.) brazilien-
sis, L. (V.) guyanensis, and L. (V.) panamensis were found to
be 3–5-fold more sensitive to SbV (average ED50, !5 mg/mL)
than L. (L.) major, L. (L.) tropica, and L. (L.) mexicana [10].
Hence, we determined that it was important to use a reference
strain of the same, or close, species—L. (V.) braziliensisM2903.
By comparison with this reference strain, isolates presenting at
least 6-fold lower sensitivity to SbV (considered to be resistant
to SbV) were encountered in 4 species of subgenus Viannia: L.
(V.) braziliensis, L. (V.) guyanensis, L. (V.) lainsoni, and L. (V.)
peruviana.
However, a more surprising result was the high frequency of
SbV-resistant strains within the present sample: 28 of 35 isolates
of all species and 22 of 26 L. (V.) braziliensis isolates. This con-
trasts with a previous report [15] in which 3 of 19 isolates were
resistant before treatment and 7 of 19 were resistant after treat-
ment failure. These differences could be due to experimental
procedures, to species factors (L. [V.] panamensis was not in-
cluded in our study), or to geographical variation, if hot spots
of SbV resistance exist in Peru. The latter hypothesis was not
supported by our results, given that all of the Peruvian SbV-
resistant parasites appeared to be geographically spread over the
territory covered by the present study. Interestingly, we saw a
totally different picture of parasite drug susceptibility after ex-
posure to SbIII, the reduced and active component of the drug.
Indeed, 16 of 21 tested isolates of Viannia subgenus and 14 of
17 L. (V.) braziliensis isolates appeared to be sensitive to SbIII.
If a strain is resistant to SbV but sensitive to SbIII, can it be
classed as truly resistant to antimonials? This argument may be
resolved as more becomes known about the mechanism of action
of antimonials and the role of various host factors. In the mean-
time, it might be wise to clearly defin the terms of resistance
at the outset of any future study or report and to make a clear
distinction between real resistance caused by exposure to drug
and intrinsic unresponsiveness.
A fin analysis of our results of SbV and SbIII susceptibility
has already given some clues about the mechanisms leading to
SbV/SbIII resistance. Indeed, the observation of 3 combinations
of SbV and SbIII sensitivity phenotypes (5S3S, 5R3S, and 5R3R)
and the absence in the present sample of the 5S3R combination
suggests a cumulative process in which parasites would become
resistant to SbV firs and resistant to SbIII second. A similar
observation was made in L. (L.) donovani clinical isolates from
Nepal (S. Rijal, V.Y., and J.-C.D., data not shown). It is generally
accepted that all pentavalent antimonials are prodrugs that re-
quire biological reduction to the trivalent form (SbIII) for an-
tileishmanial activity, although the site (amastigote or macro-
phage) and mechanism of reduction remain controversial [14].
Accordingly, resistance to SbV and not to SbIII would imply
a lower activation in the parasite, whereas the cumulated re-
sistance to SbIII could be due to an additional and broader
spectrum of mechanisms, such as modifie influ or efflu and
change of target [28].
The high frequency of SbV resistance raises a particular con-
cern in the generally accepted zoonotic context of leishmaniasis
in the Viannia subgenus. Indeed, in this situation, humans are
generally considered to be a “dead end” for transmission, and
most of the parasites are in animals in which drug pressure is
nonexistent. One explanation for these results may be a shift
from zoonotic to anthroponotic transmission, as has been hy-
pothesized by other researchers [15]. Several reports have sug-
gested that some transmission cycles of neotropical Leishmania
tend toward domestication [29]. However, if this were the case,
geographical clustering of isolates according to their phenotype
would be expected, and this was not seen in the present study.
Alternatively, in a real zoonotic context, drug resistance could
be acquired by many patients (secondary resistance), as has
been shown in Colombia by the isolation—from the same pa-
tient—of sensitive and resistant parasites before and after treat-
ment failure, respectively [15]. This could be due to suboptimal
therapy, poor quality of the drug, or other factors. This was
controlled for as much as possible in the present study. (1)
Commercial brands (Glucantime) or generic sodium stiboglu-
conate was used, and, in the latter case, each batch was shown
to contain the adequate content of SbV (IDA). (2) A directly
observed therapy protocol was used to ensure the correct ad-
ministration of the drug. Furthermore, we encountered in L.
(V.) braziliensis a high proportion (15/17) of primary SbV-
resistant parasites (isolated before supervised treatment from
patients with no history of antimonial therapy). A last expla-
nation compatible with zoonotic transmission could be that
the observed SbV resistance does not result from previous con-
tact with the drug but could be a secondary effect of another
phenomenon. The recent demonstration of cross-resistance to
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antimony and nitric oxide [30] supports this possibility and
should be further explored.
Another major findin was the lack of correlation between
in vitro susceptibility to antimony and the clinical outcome of
therapy. In a recent report on resistance to SbV in L. (V.)
panamensis, a correlation of 40% was observed with treatment
failure [15], but the occurrence of resistant strains among pa-
tients responding to the treatment was not reported. Our data
show that, of 13 cured patients, 11 were infected with SbV-
resistant L. (V.) braziliensis parasites. Obviously, our sample
size could be further increased to confi m this lack of corre-
lation, bur other explanations should be considered. The pos-
sibility that SbV susceptibility is not the correct phenotype to
correlate with treatment outcome should not be excluded: in-
deed, of 10 cured patients for whomwe had isolates with known
SbV and SbIII susceptibility phenotypes, it appeared that 9
isolates were sensitive to SbIII. Nevertheless, we did not fin
any correlation between SbIII susceptibility and clinical out-
come. The fact that many of our isolates were obtained before
treatment could be a second explanation, if secondary resistance
were the most frequent situation (in that case, the pretreatment
sensitive isolates would obviously not correlate with treatment
failure). However, as was mentioned above, most of the pre-
treatment isolates were already resistant in the present study.
A third explanation could be that treatment failure is not due
simply to the degree of parasite sensitivity to antimony but also
to host factors. This is supported by previous reports that have
shown that a poor response to antimonial therapy in patients
infected with L. (V.) braziliensis was associated with a low lym-
phoproliferative response [31]. This possible explanation is fur-
ther strengthened by recent trials that have demonstrated that
the administration of antimony plus topical imiquimod (an
innate immune-response modulator) to subjects for whom an
initial course of antimony therapy failed accelerated the reepi-
thelization of lesions and improved scar quality [32, 33].
The present results demonstrate the need for more stan-
dardization in studies of drug resistance and its link to treat-
ment outcome. This concerns the in vitro susceptibility assays
themselves (e.g., those based on intracellular amastigotes that
measure SbV and SbIII) but also the clinical aspects themselves,
protocols, and, most of all, definitions Further work should
be performed in Peru, to confi m our data in a larger sample,
and in other countries in the region. Ideally, they should be
performed in a multicenter and multidisciplinary context, and
they should certainly contain an immunological component,
to consider the respective weight of parasite and human factors
in the fina treatment outcome.
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